RxDoctor Payments Data

Fernando Cuascut, MD

Neurology · Houston, TXNPI 1134531692

Payments from drug & device makers

$494,525in general payments, 2019–2025

Across 230 payments — averaging $2150.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$374K
  • Biogen$49K
  • Amgen$21K
  • EMD Serono, Inc.$18K
  • Genentech USA, Inc.$16K
  • Novartis$8K
  • plus $9K from 4 others
$1,611in research payments, 2019–2025

Across 2 payments — averaging $805.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$2K

What the payments were for

  • Consulting fees$49,80155%
  • Speaking & faculty fees$17,60019%
  • Grants$1,5002%
  • Travel & lodging$6,0277%
  • Food & beverage$12,18213%
  • Charitable contribution$4,0004%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.41$373,918
Biogen43$48,776
Amgen(2 entities)30$21,346
EMD Serono, Inc.38$17,632
Genentech USA, Inc.19$16,315
Novartis34$7,658
Sanofi11$6,164
TG Therapeutics, Inc.8$2,426
AstraZeneca2$194
AbbVie4$96

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$494,525 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$1,026,477
Medicare patients
193
Services billed
68,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab105$1,192,485
VumerityDiroximel Fumarate24$218,317
GlatopaGlatiramer Acetate33$75,462
Dalfampridine ErDalfampridine96$49,597
Dimethyl Fumarate17$44,215
Glatiramer Acetate21$30,304
Baclofen227$4,871
Gabapentin196$4,185
Armodafinil35$3,237
Modafinil71$2,526
AmantadineAmantadine Hcl39$1,267
Tizanidine Hcl61$1,192
Pregabalin40$871
Lacosamide17$687
Bupropion XlBupropion Hcl26$563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$48,776$218,31724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →